肾臟药物市场：依给药途径、按药物类别、按分销管道、按地区

预计2024年全球肾臟药物市场规模为172亿美元，预计2031年将达269亿美元，2024年至2031年复合年增长率为6.6%。

图 1. 2024 年肾臟药物市场占有率（%），依地区划分

由于全球肾臟疾病盛行率不断上升，全球肾臟药物市场正在强劲成长。肾臟或肾臟疾病已成为一个主要的公共卫生问题，对老年人口的影响尤其严重。根据美国肾臟资料系统的数据，超过 661,000 名美国患有终末期肾病，而且这一数字预计在不久的将来还会增加。此外，糖尿病和高血压等疾病是肾臟疾病的主要原因，也推动了对用于治疗和管理的肾臟药物的需求。製药公司正在积极致力于开发新的有效药物，以满足不断增长的需求。

市场动态：

全球肾病药物市场的成长是由更容易患慢性肾臟病的老年人口增加、糖尿病和高血压患病率上升、人们对肾病的认识提高以及旨在开发新治疗方法的研究工作取得进展推动的。然而，药物核准的严格法规环境以及与肾臟药物相关的高成本可能会阻碍市场成长。新兴国家不断增长的医疗保健支出可能为市场进入者提供机会。製药公司正在大力投资管道药物的临床试验，以扩大产品系列，并进行併购以提高其市场占有率。

本研究的主要特点

• 该报告对全球肾臟药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球肾臟药物市场的主要企业。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球肾臟药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员可以透过用于全球肾臟药物市场分析的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行概述
• 一致的机会地图 (COM)

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球肾臟药物市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球肾臟病药物市场，依途径，2019-2031（十亿美元）

• 介绍
• 口服
• 胃肠外的
• 其他的

第六章全球肾臟病药物市场，依药物类别，2019-2031（十亿美元）

• 介绍
• ACE抑制剂
• 血管收缩素受体阻断剂 (ARB)
• B阻断剂
• 钙离子通道阻断剂
• 袢利尿剂
• 红血球生成刺激因子（ESA）
• 磷酸盐粘合剂
• 其他的

第七章全球肾臟药物市场，按分销管道，2019-2031（十亿美元）

• 介绍
• 医院药房
• 零售药房
• 网路药房

第八章2019-2031年全球肾臟药物市场（按地区）（十亿美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• 公司简介
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson &Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck &Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG &Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

第10章分析师建议

• 升起和降落
• 综合机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法

Global nephrology drugs market is estimated to be valued at USD 17.2 Bn in 2024 and is expected to reach USD 26.9 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Figure 1. Nephrology Drugs Market Share (%), By Region, 2024

Global nephrology drugs market has been witnessing robust growth due to rising prevalence of kidney diseases around the world. Kidney or renal diseases have emerged as a major public health issue, disproportionately affecting the elderly population. According to the U.S. Renal Data System, over 661,000 Americans have end-stage renal disease with the number expected to grow in the near future. Moreover, conditions like diabetes and hypertension, which are the leading causes of kidney diseases, boosts demand for nephrology medications for treatment and management. Pharmaceutical companies are actively engaged in developing novel and effective drugs to cater to growing demand.

Market Dynamics:

Global nephrology drugs market growth is primarily driven by increasing geriatric population susceptible to chronic kidney diseases, rising prevalence of diabetes and hypertension, growing awareness about kidney ailments, and ongoing research towards development of new treatment options. However, stringent regulatory environment for drug approval and high costs associated with renal medication can hamper the market growth. Growing healthcare expenditure of emerging economies can offer opportunities for market players. Pharmaceutical companies are investing heavily in clinical trials of pipeline drugs to expand their product portfolios, and are engaging in mergers and acquisitions to strengthen their market presence.

Key features of the study:

• This report provides in-depth analysis of the global nephrology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nephrology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen, Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd., Sanofi S.A, AbbVie Inc., Novartis AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nephrology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephrology drugs market

Detailed Segmentation-

• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Drug Class
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Amgen Inc.
  • F.Hoffmann-La Roche Ltd
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Nephrology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Nephrology Drugs Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn) Myoglobin
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Nephrology Drugs Market, By Drug Class, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• ACE Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Angiotensin Receptor Blockers (ARBs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• B-Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Loop Diuretics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Phosphate Binders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Nephrology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Nephrology Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Genzyme Corporation
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • Shire Pharmaceuticals Limited
  • Keryx Biopharmaceuticals Inc.
  • Otsuka Pharmaceutical Co. Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Reference and Research Methodology

• References
• Research Methodology
• About us and Sales Contact